Anthony D Verderosa

List of Publications by Year
in descending order

15	554	1163117 8	996975 15
papers	citations	h-index	g-index

17	17	17	797
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bacterial Biofilm Eradication Agents: A Current Review. Frontiers in Chemistry, 2019, 7, 824.	3.6	338
2	Combination Therapies for Biofilm Inhibition and Eradication: A Comparative Review of Laboratory and Preclinical Studies. Frontiers in Cellular and Infection Microbiology, 2022, 12, 850030.	3.9	42
3	Ciprofloxacin-nitroxide hybrids with potential for biofilm control. European Journal of Medicinal Chemistry, 2017, 138, 590-601.	5.5	38
4	Synthesis and Evaluation of Ciprofloxacin-Nitroxide Conjugates as Anti-Biofilm Agents. Molecules, 2016, 21, 841.	3.8	30
5	Nitroxide Functionalized Antibiotics Are Promising Eradication Agents against Staphylococcus aureus Biofilms. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	19
6	Moraxella catarrhalis NucM is an entry nuclease involved in extracellular DNA and RNA degradation, cell competence and biofilm scaffolding. Scientific Reports, 2019, 9, 2579.	3.3	15
7	Eradicating uropathogenic Escherichia coli biofilms with a ciprofloxacinâ€“dinitroxide conjugate. MedChemComm, 2019, 10, 699-711.	3.4	12
8	Thermoresponsive Polymerâ€“Antibiotic Conjugates Based on Gradient Copolymers of 2-Oxazoline and 2-Oxazine. Biomacromolecules, 2021, 22, 5185-5194.	5.4	11
9	Profluorescent Fluoroquinolone-Nitroxides for Investigating Antibioticâ€“Bacterial Interactions. Antibiotics, 2019, 8, 19.	3.7	8
10	An in vitro Reconstructed Human Skin Equivalent Model to Study the Role of Skin Integration Around Percutaneous Devices Against Bacterial Infection. Frontiers in Microbiology, 2020, 11, 670.	3.5	8
11	Isothiazoloneâ€“Nitroxide Hybrids with Activity against Antibiotic-Resistant Staphylococcus aureus Biofilms. ACS Omega, 2022, 7, 5300-5310.	3.5	8
12	Salmonella enterica BcfH Is a Trimeric Thioredoxin-Like Bifunctional Enzyme with Both Thiol Oxidase and Disulfide Isomerase Activities. Antioxidants and Redox Signaling, 2021, 35, 21-39.	5.4	7
13	A high-throughput cell-based assay pipeline for the preclinical development of bacterial DsbA inhibitors as antivirulence therapeutics. Scientific Reports, 2021, 11, 1569.	3.3	7
14	Loss of Î²-Ketoacyl Acyl Carrier Protein Synthase III Activity Restores Multidrug-Resistant Escherichia coli Sensitivity to Previously Ineffective Antibiotics. MSphere, 2022, 7, e0011722.	2.9	7
15	Antivirulence DsbA inhibitors attenuate Salmonella enterica serovar Typhimurium fitness without detectable resistance. FASEB BioAdvances, 2021, 3, 231-242.	2.4	3